New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1 ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine (NEJM) published the full results from the positive Phase 3 ASCENT-04/KEYNOTE-D19 study evaluating the ...

DynaMed Advances Clinical Decision Making with Same-Day Access to the New England Journal of Medicine

EBSCO Clinical Decisionstoday announced DynaMed®, a leading clinical decision support solution from EBSCO Information Services (EBSCO), now publishes summaries of select articles from the New England ...
Mirage News

Alliance Foundation Phase III PATINA Study in NEJM

Alliance Foundation Trials, LLC (AFT) today announced the publication of the pivotal phase III PATINA study (AFT-38) in the New ...
Medical Dialogues

Ianalumab Shows Durable Platelet Response in Primary Immune Thrombocytopenia: NEJM

More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal ...
STAT

NEJM and public health group are launching rival to CDC’s MMWR publication

Anil Oza is a general assignment reporter at STAT focused on the NIH and health equity. You can reach him on Signal at aniloza.16. In the latest bid to plug gaps in the federal government’s public ...
The Pharma Letter

Gilead Sciences publishes Trodelvy-Keytruda data in NEJM

US pharma major Gilead Sciences (Nasdaq: GILD) says The New England Journal of Medicine has published full Phase III data for ...
Morningstar

New England Journal of Medicine (NEJM) to Publish Results From Savara’s Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

New England Journal of Medicine (NEJM) to Publish Results From Savara’s Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) -- In the Largest Clinical ...